Ceapro Inc. to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 08:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights
August 26, 2021 09:00 ET
|
Ceapro Inc.
– Company continues to increase R&D activities to advance clinical and preclinical programs – – Second quarter sales of $4,409,000 compared to $4,666,000 for second quarter 2020 – – Cash...
Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan and Avenanthramides
August 23, 2021 08:05 ET
|
Ceapro Inc.
– Research focused on addressing root cause of disease and tissue damage for diseases such as COVID-19 – – Leveraging the unique expertise and methods developed by the Angiogenesis Foundation to...
Ceapro Inc. Expands Collaboration with Montreal Heart Institute (MHI) with New Clinical Study Evaluating Flagship Product, Avenanthramide
August 11, 2021 09:05 ET
|
Ceapro Inc.
- Second human trial to be conducted as part of a long-term Master Service Agreement with MHI- Phase 1 study with Ceapro’s pharmaceutical grade avenanthramide to be coordinated by MHI’s Montreal...
Ceapro Announces Results of 2021 Shareholders’ Meeting
June 01, 2021 16:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, June 01, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as a Cholesterol-Lowering Agent
May 26, 2021 08:30 ET
|
Ceapro Inc.
– Clinical study evaluating the well-known health claims of beta glucan and its potentially beneficial approach for patients to lower plasma cholesterol – – Study conducted in collaboration with the...
Ceapro Inc. Reports 2021 First Quarter Financial Results and Highlights
May 20, 2021 09:05 ET
|
Ceapro Inc.
– Maintained production operations during COVID-19 pandemic, providing customers essential products while ensuring the health and safety of Company’s employees – – Increased R&D investments...
Ceapro Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
April 22, 2021 09:05 ET
|
Ceapro Inc.
Maintained production operations during COVID-19 pandemic, providing customers with essential products and completing integration of manufacturing site, while ensuring the health and safety of...
Ceapro Inc. Announces Successful Completion of Collaborative Research and Development Program with University of Alberta
April 08, 2021 08:05 ET
|
Ceapro Inc.
– Project significantly advances broadening the application and utility of Ceapro’s proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical complexes –...
Ceapro Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
March 03, 2021 09:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, March 03, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...